Compare Citius Pharmaceuticals Inc (CTXR) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VanEck Uranium & Nuclear ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while VanEck Uranium & Nuclear ETF trades at $102.53 (market cap $3.61B). The key difference: VanEck Uranium & Nuclear ETF is far larger — about 261.8× Citius Pharmaceuticals Inc's market cap, and VanEck Uranium & Nuclear ETF is more actively traded (696,289 versus 156,684). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and VanEck Uranium & Nuclear ETF for 7 Days on average.
| CTXR | NLR | |
|---|---|---|
Market Cap | $13.79M | $3.61B |
Volume | 156,684 | 696,289 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $164.37 |
52-Week Low | $0.48 | $102.38 |
Typical Hold Time | 16 Days | 7 Days |
Enterprise Value | $3.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →
